JNJ-16241199
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].
Product Specifications
CAS Number
[604769-01-9]
Product Name Alternative
R306465
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jnj-16241199.html
Purity
99.05
Solubility
DMSO : 11.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(N(CC1)CCN1C2=NC=C(C(NO)=O)C=N2)(C3=CC=C4C(C=CC=C4)=C3)=O
Molecular Formula
C19H19N5O4S
Molecular Weight
413.45
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
HDAC1; HDAC8
Available Sizes
Explore Other Products
Browse additional items from our catalog
IL9R, ID (IL9R, Interleukin-9 receptor, CD129) (MaxLight 550) discontinued
2-Bromo-2-(2-fluorophenyl)-1-cyclopropylethanone (90% purity)